APA (7th ed.) Citation

Rohlfing, S., Aurich, M., Schöning, T., Ho, A. D., & Witzens-Harig, M. (2015). Nonpegylated liposomal doxorubicin as a component of R-CHOP is an effective and safe alternative to conventional doxorubicin in the treatment of patients with diffuse large B-Cell lymphoma and preexisting cardiac diseases. Clinical lymphoma, myeloma & leukemia, 15(8), . https://doi.org/10.1016/j.clml.2015.03.008

Chicago Style (17th ed.) Citation

Rohlfing, Sarah, Matthias Aurich, Tilman Schöning, Anthony Dick Ho, and Mathias Witzens-Harig. "Nonpegylated Liposomal Doxorubicin as a Component of R-CHOP Is an Effective and Safe Alternative to Conventional Doxorubicin in the Treatment of Patients with Diffuse Large B-Cell Lymphoma and Preexisting Cardiac Diseases." Clinical Lymphoma, Myeloma & Leukemia 15, no. 8 (2015). https://doi.org/10.1016/j.clml.2015.03.008.

MLA (9th ed.) Citation

Rohlfing, Sarah, et al. "Nonpegylated Liposomal Doxorubicin as a Component of R-CHOP Is an Effective and Safe Alternative to Conventional Doxorubicin in the Treatment of Patients with Diffuse Large B-Cell Lymphoma and Preexisting Cardiac Diseases." Clinical Lymphoma, Myeloma & Leukemia, vol. 15, no. 8, 2015, https://doi.org/10.1016/j.clml.2015.03.008.